哈尔滨医科大学徐万海等研究人员合作发现，在体自组装的双特异性荧光探针可用于早期检测膀胱癌及其转移。该研究于2024年10月31日在线发表于国际一流学术期刊《科学通报》。

研究人员报告了一种基于糖肽的双特异性荧光探针（bsProbe），用于早期检测膀胱癌及其转移。通过同时识别（肿瘤和肿瘤微环境）和在体自组装，bsProbe的肿瘤富集度（12.3% ID/g）明显增加，约为CXCR4特异性荧光探针（sProbe）的6倍，这表明bsProbe在现有肿瘤转移检测探针中的明显优势。此外，bsProbe显著扩大了肿瘤诊断窗口，并增强了检测信噪比（SNR约为9.5），允许对肺微转移（约1 mm）、精确识别肿瘤边界和正位肿瘤模型中的微肿瘤进行早期诊断。更重要的是，bsProbe在195例膀胱癌患者的临床标本中显示出90.48%的特异性和92.22%的灵敏度，能够区分恶性与良性标本。

总之，这种新颖的协同靶向（CD206×CXCR4）策略为早期检测膀胱癌及其转移提供了一种吸引人的方法，并可能进一步扩展至临床隐匿肿瘤的影像引导手术。

据介绍，肿瘤转移占肿瘤相关死亡的90%以上，这促使了用于区分肿瘤与正常组织的荧光标记肿瘤特异性分子成像剂的开发。然而，仅通过跟踪肿瘤标记物来早期检测转移病灶已被证明是具有挑战性的。

附：英文原文

Title: In vivo self-assembled bispecific fluorescence probe for early detection of bladder cancer and metastasis

Author: Hong-Wei An c, Hao Wang c, Wanhai Xu a

Issue&Volume: 2024/10/31

Abstract: Tumor metastasis accounts for over 90% of tumor-related deaths, prompting the development of fluorescently labeled tumor-specific molecular imaging agents for differentiating tumors from normal tissues. However, early detection of metastasis lesions by tracking tumor markers alone has proven to be challenging. Herein, we reported a glycopeptide-based bispecific fluorescence probe (bsProbe) for earlier detection of bladder cancer and metastasis. By simultaneously recognition (tumor & tumor microenvironment) and in vivo self-assembly, the tumor accumulation of bsProbe (12.3% ID/g) was obviously increased by ～6 fold compared with that in CXCR4 specific fluorescence probe (sProbe), indicating the obvious advantages of bsProbe over existing tumor metastasis detection probes. Additionally, bsProbe substantially broadens the tumor diagnosis window and enhances the detection signal to noise ratio (SNR: approximately 9.5), permitting early diagnosis of lung micro-metastasis (～1 mm), precise identifying of tumor boundaries and micro-tumors in orthotopic tumor models. More importantly, bsProbe was demonstrated to distinguish malignant from benign specimen with a specificity of 90.48% and sensitivity of 92.22% in 195 clinical specimens of bladder cancer patients. Taken together, this novel synergetic targeting (CD206 × CXCR4) strategy provides an attractive method for earlier detection of bladder cancer and metastasis, which might be further extended to the imaging-guided surgery of clinical invisible tumors.

DOI: 10.1016/j.scib.2024.10.032

Source: https://www.sciencedirect.com/science/article/abs/pii/S2095927324007928